CTNNA2 Antibody

Research Applications

CTNNA2 antibodies are utilized across diverse experimental workflows:

Key Applications

• Western Blot (WB): Detects CTNNA2 in lysates from human, mouse, and rat tissues (e.g., MCF7 cells, neuroblastoma models) .

• Immunohistochemistry (IHC): Visualizes protein localization in brain, pancreas, and tumor tissues .

• Functional Studies:

  • Silencing or overexpressing CTNNA2 modulates laminin-dependent adhesion and invasiveness in head and neck squamous cell carcinoma (HNSCC) .

  • Low CTNNA2 expression correlates with neuroblastoma relapse in non-MYCN-amplified patients .

Cancer Biology

• Tumor Suppression: CTNNA2 loss promotes β-catenin phosphorylation, enhancing Wnt pathway activity and tumor invasion . In neuroblastoma, reduced CTNNA2 levels predict poor relapse-free survival .

• Mutation Impact: Mutants like CTNNA2-S132Y increase Matrigel invasion in HNSCC, mimicking pathogenic phenotypes .

Neurological Disorders

CTNNA2 regulates synaptic plasticity and neuronal migration, with disruptions linked to cortical dysplasia .

Performance Notes

• Storage: Stable at -20°C in glycerol-containing buffers .

• Validation: Supported by knockdown/overexpression studies and structural homology .

Recent Advances (2023–2025)

• Structural Insights: AlphaFold predictions reveal CTNNA2’s actin-binding domain architecture, aiding antibody epitope mapping .

• CPTAC Assays: Targeted proteomics (CPTAC-1756) quantify CTNNA2 in ovarian cancer, showing reproducible detection with <10% CV .

• Therapeutic Exploration: Antibodies like ab76015 enable studies on CTNNA2’s role in suppressing Arp2/3-mediated actin polymerization, relevant to metastasis .

Limitations and Future Directions

• Species Restriction: Most antibodies lack cross-reactivity beyond human/mouse/rat .

• Functional Variants: Impact of splice isoforms (e.g., NP_001269526.1) on antibody specificity requires further validation .